Biogen Q2 revenue flat at $2.47B; Non-GAAP EPS up 31% to $5.28; raises FY2024 guidance

BIOGEN INC.

2024-Q2 EPS reported $6.70 revenue$4,755,400,000

Q2 total revenue $2,465M flat YoY; GAAP diluted EPS $4.00 (-2%), Non-GAAP diluted EPS $5.28 (+31%).
Core pharma revenue up 5% actual/6% CC; LEQEMBI global in-market sales ~$40M (US ~$30M).
SKYCLARYS rev $100M, ZURZUVAE rev $15M; completed HI-Bio acquisition expanding immunology pipeline.
Raised FY2024 Non-GAAP EPS guidance to $15.75-$16.25 (mid-point ~9% growth vs FY2023).
Retains Biosimilars business; expects operating income growth mid- to high-teen % and margin improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.